| Serial Number | 97518240 |
| Word Mark | LIFRENZAL |
| Filing Date | Monday, July 25, 2022 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Friday, August 2, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 26, 2023 |
| Goods and Services | Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease |
| Goods and Services | Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 16, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 16, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | AADi Bioscience, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Pacific Palisades, CA 90272 |
| Party Name | AADi Bioscience, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Pacific Palisades, CA 90272 |
| Event Date | Event Description |
| Friday, May 26, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, July 28, 2022 | NEW APPLICATION ENTERED |
| Tuesday, August 16, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 10, 2023 | ASSIGNED TO EXAMINER |
| Friday, May 26, 2023 | NON-FINAL ACTION E-MAILED |
| Friday, May 26, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, August 25, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, August 25, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, November 21, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, November 21, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, November 21, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, November 21, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, November 21, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 6, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 26, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 26, 2023 | PUBLISHED FOR OPPOSITION |
| Monday, January 8, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, January 8, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, January 8, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, August 2, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, August 2, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, August 2, 2024 | SOU EXTENSION 1 GRANTED |
| Friday, August 2, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, February 20, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |